Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study was set up to assess the efficacy and tolerability of a chemotherapy-immunotherapy
combination programme originally introduced by GMALL (the German cooperative group for adult
acute lymphoblastic leukemia)in 2002, to improve remission rate, overall and disease-free
survival rates of adult patients with Burkitt's leukemia and lymphoma.
The therapy includes a maximum of six chemotherapy courses (two with high doses of
methotrexate and cytarabine) plus anti-CD20 antibody (Rituximab, up to 8 total doses),
supplemented by local radiation therapy in the case of initial mediastinal or central nervous
system (CNS) involvement or a residual tumor after chemotherapy.